The effect of inofolic supplementation on women with polycystic ovarian syndrome (Pcos): A randomized clinical trial study

Abstract

Objective. Polycystic ovary syndrome is a disorder in women of reproductive age and it is one of the pathological factors that play a role in the failure of laboratory fertilization (IVF). The aim of this study was to determine the effect of inofolic supplementation on women with polycystic ovary syndrome (PCOS). Material and methods. This clinical trial study was performed on 70 infertile women aged 20 to 40 years with polycystic ovary syndrome referred to the Sanandaj Besat Hospital infertility center in 2019. Patients were randomly divided into intervention and control groups. Patients in the intervention group took Clomiphene and inofolic supplement for 3 months and patients in the control group received only Clomiphene for 3 months. Various parameters such as fasting sugar, LDL, HDL, cholesterol, triglyceride and testosterone level were also measured. Results. LDL (96.6 ± 19.4 vs 105.2 ± 10.1, p = 0.02), cholesterol (158.2 ± 10.4 vs 79.8 ± 14.4, p = 0.0001) and triglycerides levels (140.1 ± 30.3 vs 160.3 ± 22.0, p = 0.002) was significantly lower in the intervention group than in the control group. The mean HDL level in the intervention group was higher than the control group (47.3 ± 7.5 vs 43.2 ± 5.1, p = 0.009). The frequency of follicles (+ 2) in the intervention group (85.7%) was higher than in the control group (37.1%) (p = 0.001). The frequency of clinical pregnancies, pregnancies leading to live births, miscarriages, and preterm births in the two groups did not differ significantly and were almost similar (P > .05). Conclusions. Inofolic supplementation improved fat profile status, fetal quality and reduced miscarriage and also increased follicles in women with polycystic ovary syndrome.